CRISPR Therapeutics AG (CRSP)
CRSPNASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$50.55
+0.4800 (+0.96%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $4.85bn
- P/E
- –
- EPS, last 4 quarters
- $-4.74
- Dividend yield
- –
- Day range
- –
- 52-week range
- $44.12 to $63.45
- Average volume
- 1.50m
- Previous close
- $50.07
Analysts
14 coveringBuy8 buy, 6 hold, 0 sell
Targets a year out average $70.54, +39.5% from here
Earnings
next estimate $-1.26Next report
Dec 2025
-19.1%
Mar 2026
-12.3%
Jun 2026
+14.6%
Sep 2026
-8.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $864.0k | $1.46m | $10.18m | $12.67m |
| Gross profit | $864.0k | $1.46m | $10.18m | $12.67m |
| Operating income | -$154.76m | -$130.25m | -$117.27m | -$130.04m |
| Net income | -$130.61m | -$122.93m | -$91.15m | -$111.44m |
Last four quarters: revenue $25.17m, margin -1812.1%, free cash flow -$376.71m
News
8 latest- ARK Innovation ETF Experiences Big OutflowBNK Invest · 10 hours ago
- CRISPR Highlights New Phase 1 Data For Zugo-cel In Rheumatologic Autoimmune Diseases RTTNews · 20 hours ago
- CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItZacks · 4 days ago
- Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 YearsThe Motley Fool · 4 days ago
- CRSP's Q3 Loss Wider Than Expected, Sales Beat EstimatesZacks · 7 days ago
- VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View RaisedZacks · 7 days ago
- CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
- Casgevy Starts Paying Off for CRISPR: Rapid Earnings ReactionThe Motley Fool · Nov 2, 2026
The company
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY (exagamglogene autotemcel [exa-cel]), the world's first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- crisprtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.